Medutest result on a Qingdao survodutide lot lands 2.7 points above the supplier’s stated figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 2 of 4 of this archive, newest first.
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Efficacy was never the question in this appraisal. Duration of treatment was.
Follow the resin, not the catalogue.
The evidence base is thin and the document says so, which is to its credit.
Efficacy was never the question in this appraisal. Duration of treatment was.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The document is four pages. Three of them are about dates.
The observation that closes a facility is rarely the dramatic one.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The result is unremarkable. What the report states alongside it is not.
The observation that closes a facility is rarely the dramatic one.
The route did not close because of a rule about peptides.
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
The observation that closes a facility is rarely the dramatic one.
The document is four pages. Three of them are about dates.
Reported from the sessions, and from the two hours afterwards.
The observation that closes a facility is rarely the dramatic one.
The route did not close because of a rule about peptides.
Follow the resin, not the catalogue.
A proper account of an operation that existed, and of what closing it cost.
Reported from the analysis, not from a warning notice.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The route did not close because of a rule about peptides.
Efficacy was never the question in this appraisal. Duration of treatment was.
Follow the resin, not the catalogue.
The document is four pages. Three of them are about dates.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Reported from the analysis, not from a warning notice.